- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
BMJ ad framed as an acquisition announcement for Dificlir was ruled promotional. It lacked prescribing information and an…
Forxiga website and rep messaging implied all patients can start 10mg with no uptitration. Key 5mg start for…
A third-party promotional webpage had a non-functioning single-click PI link for Pradaxa/Praxbind for ~3 weeks. An earlier email…
Six amalgamated complaints. Breaches found for a UK “think tank” meeting (uncertified promotional content; ‘cure’ implication) and LinkedIn…
Complaint alleged a senior employee’s LinkedIn ‘Experience’ section promoted Enhertu to the public and off-label, using terms like…
An anonymous representative alleged pressure to promote Aldara off-licence and raised concerns about call-rate targets and a GP…
Novartis’ UK press release headline implied an overall survival benefit for Femara vs tamoxifen despite non-significant ITT results…
Allergan’s Botox monograph made comparative claims vs Dysport (and referenced Xeomin). Panel found several claims misleading/unsubstantiated and ruled…
A trust clinical director alleged a Pfizer rep was intimidating and applied inappropriate pressure when trying to access…
Cephalon’s internal congress feedback note described “clubbing” and late-night bars with HCPs and urged “lets make sure they…
One real case. One key lesson. Every week — free.